» Articles » PMID: 31562808

Analyses of an Epigenetic Switch Involved in the Activation of Pioneer Factor FOXA1 Leading to the Prognostic Value of Estrogen Receptor and FOXA1 Co-expression in Breast Cancer

Overview
Specialty Geriatrics
Date 2019 Sep 29
PMID 31562808
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Forkhead box protein A1 () is a pioneer factor of estrogen receptor α (ER)-chromatin binding and function, yet the role of in breast cancer and the underlying molecular mechanisms have not yet been elucidated. To evaluate gene expression alterations during breast carcinogenesis, expression was analyzed using the Serial Analysis of Gene Expression Genie suite, a gene expression profiling interactive analysis, and Oncomine analyses. The correlation between methylation and expression was analyzed using the MEXPRESS tool and UCSC Xena browser. Then, the expression and prognostic value of FOXA1 was validated by our own breast cancer samples using RT-PCR. We obtained the following important results. (1) The expression level of was significantly higher in breast cancer than normal tissues. (2) ER, PR, HEGR-2, and nodal status were positively correlated with expression. (3) Among patients with ER+ tumors, those with higher expression levels had better survival probabilities. (4) The major mutation type in in breast cancer samples was missense mutations. (5) expression was significantly higher in ER+ breast tumors than in ER- tumors or normal tissues. Our findings suggest that the aberrant DNA hypomethylation of promoter regions is one mechanism underlying the aberrant expression of in ER+ breast cancer, which might be a potential indicator of favorable prognosis.

Citing Articles

Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response.

Qin Q, Zhou Y, Guo J, Chen Q, Tang W, Li Y Genome Med. 2024; 16(1):47.

PMID: 38566132 PMC: 10985907. DOI: 10.1186/s13073-024-01318-3.


ARL11 correlates with the immunosuppression and poor prognosis in breast cancer: A comprehensive bioinformatics analysis of ARL family members.

Xie N, Shu Q, Wang Z, Huang X, Wang Y, Qin B PLoS One. 2022; 17(11):e0274757.

PMID: 36367890 PMC: 9651578. DOI: 10.1371/journal.pone.0274757.


MicroRNA-100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1.

Xie H, Xiao R, He Y, He L, Xie C, Chen J Oncol Lett. 2021; 22(6):816.

PMID: 34671430 PMC: 8503813. DOI: 10.3892/ol.2021.13077.


miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1.

Cui X, Jing X, Liu J, Bi X, Wu X Mol Med Rep. 2020; 22(6):5155-5162.

PMID: 33174054 PMC: 7646966. DOI: 10.3892/mmr.2020.11590.


Cell-specific expression of gene by FOXA1 in the glucocorticoid receptor pathway.

Chung Y, Jin H, Jeong K Int J Immunopathol Pharmacol. 2020; 34:2058738420946192.

PMID: 32838581 PMC: 7450284. DOI: 10.1177/2058738420946192.


References
1.
Theodorou V, Stark R, Menon S, Carroll J . GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2012; 23(1):12-22. PMC: 3530671. DOI: 10.1101/gr.139469.112. View

2.
Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

3.
Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G . bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2011; 131(3):765-75. DOI: 10.1007/s10549-011-1457-7. View

4.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

5.
Cui X, Yi Q, Jing X, Huang Y, Tian J, Long C . Mining Prognostic Significance of MEG3 in Human Breast Cancer Using Bioinformatics Analysis. Cell Physiol Biochem. 2018; 50(1):41-51. DOI: 10.1159/000493956. View